Citations

Clear

1011 citation(s) found for "Barry, WT".

Quantitative Determination of Regional Left Ventricular Wall Dynamics by Roentgen Videometry
Dumesnil, Jean G., Ritman, Erik L., Frye, Robert L. , Gau, Gerald T., Rutherford, Barry D., Davis, George D.

Mayo Clinic

Circulation | June 11, 2012 | Volume: 50 | Issue: 4 | Pages: 700-708

10.1161/01.cir.50.4.700 | PMID 4424756 Get It

The use of roentgen videometry as a means of studying regional left ventricular wall dynamics and performance was evaluated in 32 patients undergoing coronary arteriography. Nine patients had normal coronary arteriograms and hemodynamic findings (group 1), 8 patients had generalized decrease in left ventricular contraction and abnormal hemodynamic findings (group 2), and 15 patients with coronary artery disease had regional wall dynamics abnormalities (group 3). Sixty-per-second determinations of wall thickness were performed in selected sites of the left ventricle. Measurements performed included end-diastolic wall thickness (EDTw), mean and peak rates of systolic wall thickening (m and p dTw/dt), and fractional systolic increase in wall thickness (ΔTw/EDTw). In patients with uniformly performing ventricles (groups 1 and 2), these parameters correlated well with other parameters of ventricular function. Best distinction between the "normal" group (group 1) and the "abnormal" group (group 2) was achieved when the rates of thickening (m and p dTw/dt) were utilized ( P < 0.001). In patients of group 3, three types of abnormal regional wall dynamics could be determined and quantified objectively: hypokinesia (decreased p dTw/dt), akinesia (p dTw/dt = 0), and dyskinesia (p dTw/dt < 0). The severity of the abnormality of the wall dynamics correlated well with the presence or absence of a previous infarction on the electrocardiogram, and the anatomic location was strongly correlated with the distribution and severity of coronary artery lesions within a given ventricle.
Combined One-Stage Coronary Artery and Valvular Surgery
Merin, Gideon, Danielson, Gordon K., Wallace, Robert B. , Rutherford, Barry D., Pluth, James R.

Mayo Clinic

Circulation | June 11, 2012 | Volume: 48 | Issue: 1s3 | Pages: No page available

10.1161/01.cir.48.1s3.iii-173 | PMID 4541746 Get It

Fifty patients underwent correction of one or two valvular lesions with concomitant insertion of one to three aortocoronary vein bypass grafts. Hospital mortality was 14% and late mortality was 10%. Factors influencing operative mortality were: (1) mitral valve replacement after myocardial infarction; (2) complete obstruction of a coronary artery preoperatively; (3) high left ventricular end-diastolic pressure at rest preoperatively in patients with mitral valve disease; and (4) use of a single aortocoronary graft in the presence of multiple-vessel disease. For patients with significant associated valvular and coronary artery disease, combined correction yields results that appear sufficiently encouraging, judged by mortality and follow-up, to warrant its continued use in selected cases.
Effect of Aspirin on Brachial Artery Occlusion following Brachial Arteriotomy for Coronary Arteriography
Hynes, Kieran M., Gau, Gerald T., Rutherford, Barry D., Kazmier, Francis J., Frye, Robert L.

Mayo Clinic

Circulation | June 11, 2012 | Volume: 47 | Issue: 3 | Pages: 554-557

10.1161/01.cir.47.3.554 | PMID 4571057 Get It

The effect of oral aspirin in doses known to influence in vitro platelet aggregation was evaluated in patients undergoing brachial artery catheterization. Neither arterial thrombus formation nor pulse reduction was affected in patients given aspirin when compared to controls. Aspirin in small doses does not decrease the incidence of vascular occlusion after brachial artery catheterization.
The Value of Monitoring Pulmonary Artery Pressure for Early Detection of Left Ventricular Failure Following Myocardial Infarction
Rutherford, Barry D., McCann, William D. , O'DONOVAN, T. PAUL B.

Mayo Clinic

Circulation | June 11, 2012 | Volume: 43 | Issue: 5 | Pages: 655-666

10.1161/01.cir.43.5.655 | PMID 5578842 Get It

Flow-directed catheters recorded serial changes in mean pulmonary artery pressure (PA) every 4 to 6 hours in 25 patients during the first 4 or 5 days following acute myocardial infarction. On the basis of the PA on admission, patients were divided into three groups. Patients in group 1 had normal PA (10-20 mm Hg) and maintained a stroke volume index (SVI)>35 ml/min/m 2 , a pulmonary artery oxygen saturation (MVSO 2 )>70%, and a normal cardiac index, arterial oxygen saturation, p H, and P CO CO2 . They developed only minor arrhythmias, no heart failure, and none died. Group 3 consisted of one patient with abnormally low PA (<10 mm Hg) who was hypovolemic. Group 2, those patients with elevated PA (>20 mm Hg) who maintained this elevation over the first 48 hours of monitoring, or showed progressive elevation prior to this, had SVI<35 ml/min/m 2 , MVSO 2 <70%, cardiac index<3 liters/min/m 2 , arterial desaturation, and respiratory alkalosis. They demonstrated clinical evidence of heart failure, had major arrhythmias, and 25% died. Three patients with elevated PA on admission spontaneously returned this pressure to normal over the first 48 hours of monitoring. Each of these patients maintained normal hemodynamics and had a good prognosis. PA was always elevated prior to the usual clinical signs of left ventricular failure. We conclude that PA provides a reliable early objective measure of left ventricular failure and is, therefore, an excellent guide to therapy.
Assessment of Permanent Dual-Chamber Pacing as a Treatment for Drug-Refractory Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy
Maron, Barry J. , Rakowski, Harry , Josephson, Mark E., Kieval, Robert S., Nishimura, Rick A. , McKenna, William J.

Mayo Clinic

Circulation | June 11, 2012 | Volume: 99 | Issue: 22 | Pages: 2927-2933

10.1161/01.cir.99.22.2927 | PMID 10359738 Get It

Background —Dual-chamber pacing (DDD) has been proposed as a treatment alternative to surgery for severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), based largely on uncontrolled studies. Methods and Results —This prospective, multicenter trial assessed pacing in 48 symptomatic HCM patients with ≥50 mm Hg basal gradient, refractory to drug therapy. Patients were randomized to 3 months each of DDD pacing and pacing backup (AAI-30) in a double-blind, crossover study design, followed by an uncontrolled and unblinded 6-month pacing trial. With randomization, no significant differences were evident between pacing and no pacing for subjective or objective measures of symptoms or exercise capacity, including NYHA functional class, quality of life score, treadmill exercise time or peak oxygen consumption. After 6 additional months of unblinded pacing, functional class and quality of life score were improved compared with baseline ( P <0.01), but peak oxygen consumption was unchanged. Outflow gradient decreased 40%, 82±32 mm Hg to 48±32 mm Hg ( P <0.001), and was reduced in 57% of patients but showed no change or an increase in 43%. At 12 months, 6 individual patients (12%) showed improved functional capacity; each was 65 to 75 years of age. Left ventricular wall thicknesses in the overall study group showed no remodeling between baseline (22±5 mm) and 12 months (21±5 mm; P= NS). Conclusions —(1) Pacing cannot be regarded as a primary treatment for obstructive HCM; (2) with randomization, perceived symptomatic improvement was most consistent with a substantial placebo effect; (3) longer, uncontrolled pacing periods were associated with some subjective benefit but unaccompanied by objective improvement in cardiovascular performance and should be interpreted cautiously; (4) modest reduction in outflow gradient was achieved in most patients; and (5) a small subset (12%) ≥ 65 years of age showed a clinical response, suggesting that DDD pacing could be a therapeutic option for some elderly patients.
Geoffrey O. Hartzler, MD
Rutherford, Barry D., Kahn, Joel K., Strelow, David, Holmes, David R. , Strelow, David A.

Mayo Clinic

Circulation | June 11, 2012 | Volume: 125 | Issue: 23 | Pages: 2958-2960

10.1161/circulationaha.112.113274 Get It

Lentiviral vectors: basic to translational
Sakuma, Toshie, Barry, Michael A. , Ikeda, Yasuhiro , Barry, Michael A

Mayo Clinic

Biochemical Journal | April 18, 2012 | Volume: 443 | Issue: 3 | Pages: 603-618

10.1042/bj20120146 | PMID 22507128 Get It

More than two decades have passed since genetically modified HIV was used for gene delivery. Through continuous improvements these early marker gene-carrying HIVs have evolved into safer and more effective lentiviral vectors. Lentiviral vectors offer several attractive properties as gene-delivery vehicles, including: (i) sustained gene delivery through stable vector integration into host genome; (ii) the capability of infecting both dividing and non-dividing cells; (iii) broad tissue tropisms, including important gene- and cell-therapy-target cell types; (iv) no expression of viral proteins after vector transduction; (v) the ability to deliver complex genetic elements, such as polycistronic or intron-containing sequences; (vi) potentially safer integration site profile; and (vii) a relatively easy system for vector manipulation and production. Accordingly, lentivector technologies now have widespread use in basic biology and translational studies for stable transgene overexpression, persistent gene silencing, immunization, in vivo imaging, generating transgenic animals, induction of pluripotent cells, stem cell modification and lineage tracking, or site-directed gene editing. Moreover, in the present high-throughput ‘-omics’ era, the commercial availability of premade lentiviral vectors, which are engineered to express or silence genome-wide genes, accelerates the rapid expansion of this vector technology. In the present review, we assess the advances in lentiviral vector technology, including basic lentivirology, vector designs for improved efficiency and biosafety, protocols for vector production and infection, targeted gene delivery, advanced lentiviral applications and issues associated with the vector system.
Heme oxygenase‐1 regulates the immune response to influenza virus infection and vaccination in aged mice
May, Shannon M., Croatt, Anthony J., Foreman, Oded , Kennedy, Richard B. , Barry, Michael A. , Nath, Karl A. , Badley, Andrew D. , Cummins, Nathan W. , Weaver, Eric A. , Poland, Gregory A. , Weaver, Eric A , Badley, Andrew D , Barry, Michael A , Kennedy, Richard

Mayo Clinic

The FASEB Journal | April 8, 2012 | Volume: 26 | Issue: 7 | Pages: 2911-2918

10.1096/fj.11-190017 | PMID 22490782 Get It

ABSTRACT Underlying mechanisms of individual variation in severity of influenza infection and response to vaccination are poorly understood. We investigated the effect of reduced heme oxygenase‐1 (HO‐1) expression on vaccine response and outcome of influenza infection. HO‐1‐deficient and wild‐type (WT) mice (kingdom, Animalia; phylum, Chordata; genus/species, Mus musculus ) were infected with influenza virus A/PR/8/34 with or without prior vaccination with an adeno‐viral‐based influenza vaccine. A genome‐wide association study evaluated the expression of single‐nucleotide polymorphisms (SNPs) in the HO‐1 gene and the response to influenza vaccination in healthy humans. HO‐1‐deficient mice had decreased survival after influenza infection compared to WT mice (median survival 5.5 vs. 6.5 d, P =0.016). HO‐1‐deficient mice had impaired production of antibody following influenza vaccination compared to WT mice (mean antibody titer 869 vs. 1698, P =0.02). One SNP in HO‐1 and one SNP in the constitutively expressed isoform HO‐2 were independently associated with decreased antibody production after influenza vaccination in healthy human volunteers ( P =0.017 and 0.014, respectively). HO‐1 deficient mice were paired with sex‐ and age‐matched WT controls. HO‐1 affects the immune response to both influenza infection and vaccination, suggesting that therapeutic induction of HO‐1 expression may represent a novel adjuvant to enhance influenza vaccine effectiveness.—Cummins, N. W., Weaver, E. A., May, S. M., Croatt, A. J., Foreman, O., Kennedy, R. B., Poland, G. A., Barry, M. A., Nath, K. A., Badley, A. D. Heme oxygenase‐1 regulates the immune response to influenza virus infection and vaccination in aged mice. FASEB J. 26, 2911–2918 (2012). www.fasebj.org
Predicting missing biomarker data in a longitudinal study of Alzheimer disease
Lo, Raymond Y. , Jagust, William J. , Aisen, Paul , Gamst, Anthony, Soares, Holly , Montine, Tom, Thomas, Ronald G. , Walter, Sarah , Felmlee, Joel P. , Schuff, Norbert, Alexander, Gene, DeCarli, Charles , Bandy, Dan, Korecka, Magdalena , Crawford, Karen , Neu, Scott, Kornak, John , Buckholtz, Neil, Dolen, Sara, Schneider, Lon S. , Pawluczyk, Sonia, Spann, Bryan M., Brewer, James, Vanderswag, Helen, Heidebrink, Judith L. , Petersen, Ronald , Johnson, Kris , Doody, Rachelle S., Villanueva‐Meyer, Javier , Chowdhury, Munir , Bell, Karen L. , Mintun, Mark A., Schneider, Stacy, Marson, Daniel , Griffith, Randall, Grossman, Hillel, Marzloff, George, Toledo-Morrell, Leylade, Duara, Ranjan , Varón, Daniel , Roberts, Peggy, Albert, Marilyn S. , Pedroso, Julia, Toroney, Jaimie, Santi, Susan M De, Doraiswamy, P. Murali , Petrella, Jeffrey R. , Aiello, Marilyn, Clark, Christopher M. , Pham, Cassie, Nuñez, Jessica, Smith, Charles D., Given, Curtis A., Hardy, Peter , Oakley, MaryAnn, Simpson, Donna M., Ismail, M. Saleem , Brand, Connie, Richard, Jennifer, Mulnard, Ruth A., Thai, Gaby , Mc-Adams-Ortiz, Catherine, Martin-Cook, Kristen, Devous, Michael D. , Cellar, Janet S., Anderson, Heather S., Laubinger, Mary M., Bartzokis, George, Lu, Po H. , MBBCH, Neill R Graff-Radford, Parfitt, Francine, Farlow, Martin R. , Herring, Scott, Hake, Ann Marie , Dyck, Christopher H. van , MacAvoy, Martha G., Benincasa, Amanda L., Chertkow, Howard, Bergman, Howard , Hosein, Chris, Graham, Simon J. , Caldwell, Curtis, Hsiung, Ging‐Yuek Robin , Assaly, Michele, Kertesz, Andrew, Rogers, John, Trost, Dick, Bernick, Charles , Munic, Donna, Wu, Chuang‐Kuo, Johnson, Nancy , Mesulam, Marsel, Sadowsky, Carl, Villena, Teresa, Turner, Scott, Johnson, Kathleen, Behan, Kelly E., Johnson, Keith A. , Rosen, Allyson , Tinklenberg, Jared, Ashford, Wes, Sabbagh, Marwan N. , Connor, Donald J., Jacobson, Sandra A. , Jayam‐Trouth, Annapurni , Lerner, Alan J. , Hudson, Leon, Ogrocki, Paula, Fletcher, Evan, Kittur, Smita, Mirje, Seema, Borrie, Michael, Lee, T‐Y, Bartha, Dr Rob, Asthana, Sanjay , Carlsson, Cynthia M., Potkin, Steven, Preda, Adrian , Tariot, Pierre N. , Fleisher, Adam , Reeder, Stephanie, Bates, Vernice, Capote, Horacio, Rainka, Michelle, Hendin, Barry , Kataki, Maria , Zimmerman, Earl A. , Celmins, Dzintra, Brown, Alice D., Marenberg, Marjorie E., Rovner, Barry W. , Anderson, Karen, Santulli, Robert B. , Englert, Jessica, Williamson, Jeff D. , Watkins, Franklin, Ott, Brian R. , Cohen, Ronald, Salloway, Stephen , Malloy, Paul, Correia, Stephen , Rosen, Howard J. , Mintzer, Jacobo , Jack, Clifford R. , Toga, Arthur W. , Beckett, Laurel , Green, Robert C. , Donohue, Michael , Dale, Anders M. , Bernstein, Matt A. , Fox, Nick C. , Thompson, Paul M. , Chen, Kewei , Morris, John C. , Lee, Virginia M.‐Y. , Harvey, Danielle , Saykin, Andrew J. , Foroud, Tatiana , Potkin, Steven G. , Shen, Li , Kaye, Jeffrey , Quinn, Joseph F. , Lord, Joanne L. , Stern, Yaakov , Honig, Lawrence S. , Clark, David , Tang, Cheuk Ying , Shah, Raj C. , Duara, Ranjan , Rusinek, Henry , Leon, Mony J. de , López, Oscar L. , Diaz‐Arrastia, Ramon , Levey, Allan I. , Lah, James J. , Burns, Jeffrey M. , Silverman, Daniel H.S. , Johnson, Heather K. , Black, Sandra E. , Feldman, Howard , Martínez, Walter Fabián , Sperling, Reisa Anne , Rentz, Dorene M. , Killiany, Ronald , Norbash, Alexander , Nair, Anil K. , Obisesan, Thomas O. , Wang, Paul C. , Carmichael, Owen , Johnson, Sterling C. , Nguyen, Dana R. , Reeder, Stephanie, Scharre, Douglas W. , Gandy, Sam , Pearlson, Godfrey D. , Sink, Kaycee M. , Miller, Bruce L. , Preda, Adrian , Hsiung, Gink-Yuek

Mayo Clinic

Neurology | April 5, 2012 | Volume: 78 | Issue: 18 | Pages: 1376-1382

10.1212/wnl.0b013e318253d5b3 | PMID 22491869 Get It

Letter by Forfia and Borlaug Regarding Article, “Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study”
Forfia, Paul R. , Borlaug, Barry A.

Mayo Clinic

Circulation | February 27, 2012 | Volume: 125 | Issue: 8 | Pages: No page available

10.1161/circulationaha.111.064584 | PMID 22371450 Get It